2 Information about faricimab

Marketing authorisation indication

2.1 Faricimab (Vabysmo, Roche) is indicated for 'the treatment of adults with visual impairment due to diabetic macular oedema'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for faricimab.


2.3 Faricimab costs £857 for 1 vial of 120 mg per 1 ml solution for injection (excluding VAT; company submission, accessed April 2022).

2.4 The company has a commercial arrangement. This makes faricimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)